AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 10/28/22
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer's DiseaseGlobeNewsWire • 09/26/22
AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer's and Parkinson's DiseasesGlobeNewsWire • 08/24/22
Detailed Data From the Phase II Crenezumab Alzheimer's Prevention Initiative Study in Autosomal Dominant Alzheimer's Disease Presented at AAICGlobeNewsWire • 08/02/22
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 07/28/22
AC Immune Announces Upcoming Presentations at the Alzheimer's Association International ConferenceGlobeNewsWire • 07/22/22
AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goalsMarket Watch • 06/16/22
AC Immune Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer's DiseaseGlobeNewsWire • 06/16/22
AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/28/22
AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor ConferenceGlobeNewsWire • 04/27/22
AC Immune Reports Full Year 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/22/22
AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative DiseasesGlobeNewsWire • 03/21/22
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM ConferenceGlobeNewsWire • 03/16/22
AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 ProgramsGlobeNewsWire • 02/28/22
AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage TrialBenzinga • 02/15/22
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer's Vaccine in High-dose CohortGlobeNewsWire • 02/15/22
AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer's DiseaseGlobeNewsWire • 02/04/22
AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceGlobeNewsWire • 02/02/22
AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer's Vaccine Generates a Potent Immune ResponseGlobeNewsWire • 11/12/21
AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 11/10/21